The demo attained both equally its Principal endpoints, with semaglutide 2.four mg demonstrating statistically significant and top-quality improvements in liver fibrosis with no worsening of steatohepatitis, along with resolution of steatohepatitis without worsening of liver fibrosis in those with MASH as compared to placebo.1Regimen monitoring of